DexCom earnings beat by $0.03, revenue topped estimates
Saba Capital Management, L.P., a notable shareholder in abrdn Life Sciences Investors (NYSE:HQL), recently executed significant transactions involving the sale of common stock. According to a recent SEC filing, Saba Capital sold a total of 46,723 shares over two days, realizing approximately $576,754. The stock, currently trading at $12.16 with a market capitalization of $343 million, offers an attractive 15.27% dividend yield. InvestingPro analysis indicates the stock is trading near its 52-week low, with an RSI suggesting oversold conditions.
On April 1, 2025, the firm sold 17,621 shares at a price of $12.45 per share. The following day, April 2, 2025, they sold an additional 29,102 shares at $12.28 per share. These transactions left Saba Capital with a remaining balance of 3,141,682 shares. The stock currently trades at an attractive P/E ratio of 4.02, though InvestingPro data reveals some concerns about short-term obligations exceeding liquid assets, with a current ratio of 0.32.
The sales were conducted indirectly, as indicated by the nature of ownership, and were signed off by Zachary Gindes on behalf of Saba Capital Management, L.P. Boaz Weinstein, another ten percent owner, also participated in this filing. Unlock additional insights and 5 more exclusive ProTips about HQL with InvestingPro, including detailed analysis of the company’s 30-year dividend payment history.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.